Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label Clinical Trial of Intranasal Ketamine for Depression in Patients With Cancer Receiving Palliative Care (INKeD-PC Study)

NCT03410446 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT03410446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03410446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label Clinical Trial of Intranasal Ketamine for Depression in Patients With Cancer Receiving Palliative Care (INKeD-PC Study)
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Completed
Start date
July 16, 2018
Completion date
November 27, 2021
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, depression, palliative care